Literature DB >> 28242730

Behavioural and computational varieties of response inhibition in eye movements.

Vassilis Cutsuridis1.   

Abstract

Response inhibition is the ability to override a planned or an already initiated response. It is the hallmark of executive control as its deficits favour impulsive behaviours, which may be detrimental to an individual's life. This article reviews behavioural and computational guises of response inhibition. It focuses only on inhibition of oculomotor responses. It first reviews behavioural paradigms of response inhibition in eye movement research, namely the countermanding and antisaccade paradigms, both proven to be useful tools for the study of response inhibition in cognitive neuroscience and psychopathology. Then, it briefly reviews the neural mechanisms of response inhibition in these two behavioural paradigms. Computational models that embody a hypothesis and/or a theory of mechanisms underlying performance in both behavioural paradigms as well as provide a critical analysis of strengths and weaknesses of these models are discussed. All models assume the race of decision processes. The decision process in each paradigm that wins the race depends on different mechanisms. It has been shown that response latency is a stochastic process and has been proven to be an important measure of the cognitive control processes involved in response stopping in healthy and patient groups. Then, the inhibitory deficits in different brain diseases are reviewed, including schizophrenia and obsessive-compulsive disorder. Finally, new directions are suggested to improve the performance of models of response inhibition by drawing inspiration from successes of models in other domains.This article is part of the themed issue 'Movement suppression: brain mechanisms for stopping and stillness'.
© 2017 The Author(s).

Entities:  

Keywords:  antisaccade task; computational model; countermanding task; decision making; impulse control; inhibition

Mesh:

Year:  2017        PMID: 28242730      PMCID: PMC5332855          DOI: 10.1098/rstb.2016.0196

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  104 in total

1.  Effects of amphetamine on saccadic eye movements in man: possible relevance to schizophrenia?

Authors:  S M Dursun; N Wright; M A Reveley
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

2.  Activity of neurons in the lateral intraparietal area of the monkey during an antisaccade task.

Authors:  J Gottlieb; M E Goldberg
Journal:  Nat Neurosci       Date:  1999-10       Impact factor: 24.884

3.  Activity of the brain stem omnipause neurons during saccades perturbed by stimulation of the primate superior colliculus.

Authors:  N J Gandhi; E L Keller
Journal:  J Neurophysiol       Date:  1999-12       Impact factor: 2.714

4.  Composition and topographic organization of signals sent from the frontal eye field to the superior colliculus.

Authors:  M A Sommer; R H Wurtz
Journal:  J Neurophysiol       Date:  2000-04       Impact factor: 2.714

5.  Neuronal correlates for preparatory set associated with pro-saccades and anti-saccades in the primate frontal eye field.

Authors:  S Everling; D P Munoz
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

6.  Role of primate superior colliculus in preparation and execution of anti-saccades and pro-saccades.

Authors:  S Everling; M C Dorris; R M Klein; D P Munoz
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

7.  Abnormalities of internally generated saccades in obsessive-compulsive disorder.

Authors:  P Maruff; R Purcell; P Tyler; C Pantelis; J Currie
Journal:  Psychol Med       Date:  1999-11       Impact factor: 7.723

8.  Countermanding saccades in humans.

Authors:  D P Hanes; R H Carpenter
Journal:  Vision Res       Date:  1999-08       Impact factor: 1.886

9.  Saccadic eye movements in schizophrenic patients.

Authors:  B Karoumi; J Ventre-Dominey; A Vighetto; J Dalery; T d'Amato
Journal:  Psychiatry Res       Date:  1998-01-16       Impact factor: 3.222

10.  Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam.

Authors:  J F Green; D J King; K M Trimble
Journal:  J Psychopharmacol       Date:  2000-03       Impact factor: 4.153

View more
  8 in total

Review 1.  Not moving: the fundamental but neglected motor function.

Authors:  Imran Noorani; R H S Carpenter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-04-19       Impact factor: 6.237

Review 2.  Models of inhibitory control.

Authors:  Jeffrey D Schall; Thomas J Palmeri; Gordon D Logan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-04-19       Impact factor: 6.237

Review 3.  Towards a unifying mechanism for cancelling movements.

Authors:  Imran Noorani
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-04-19       Impact factor: 6.237

4.  Corrective response times in a coordinated eye-head-arm countermanding task.

Authors:  Gordon Tao; Aarlenne Z Khan; Gunnar Blohm
Journal:  J Neurophysiol       Date:  2018-02-21       Impact factor: 2.714

Review 5.  Mechanisms of saccade suppression revealed in the anti-saccade task.

Authors:  Brian C Coe; Douglas P Munoz
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-04-19       Impact factor: 6.237

6.  Probing oculomotor inhibition with the minimally delayed oculomotor response task.

Authors:  Paul C Knox; Emma Heming De-Allie; Felicity D A Wolohan
Journal:  Exp Brain Res       Date:  2018-07-30       Impact factor: 1.972

7.  Botulinum toxin treatment for bielschowsky acquired commitant esotropia in adults.

Authors:  Likun Ai; Xiaoli Chen; Ruilin Guo; Jing Li; Jinghui Wang; Yi Feng; Yiqin Guo; Jianan Wang
Journal:  BMC Ophthalmol       Date:  2022-10-04       Impact factor: 2.086

8.  The Stochastic Early Reaction, Inhibition, and late Action (SERIA) model for antisaccades.

Authors:  Eduardo A Aponte; Dario Schöbi; Klaas E Stephan; Jakob Heinzle
Journal:  PLoS Comput Biol       Date:  2017-08-02       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.